Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + S-1 + cisplatin
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
rejuvenates the skin by targeting melanin at the cellular level. Its key active ingredient is alpha-arbutin, a natural derivative of hydroquinone, which inhibits tyrosinase activity. This process reduces the production of melanin, leading to a visible reduction in dark spots, hyperpigmentation, and uneven skin tone. The serum also contains hyaluronic acid for hydration, promoting a plump and youthful appearance. It is suitable for all skin types and can be incorporated into daily skincare routines.
02
Targets
TS (Thymidylate synthase)FLT3 (Fms related receptor tyrosine kinase 3)DPYD (Dihydropyrimidine dehydrogenase)VEGFR3 (Vascular endothelial growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)BRAF V600EDNAVEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)RAF1 (c-Raf-1 (Y340D/Y341D))OPRT (Orotidine 5'-phosphate decarboxylase)
Beyond the preview
Go deeper on sorafenib + S-1 + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + S-1 + cisplatin.